Eli Lilly to acquire Bothell biotech company for $1.5 billion - The Seattle Times
Earnings
Eli Lilly is acquiring three vaccine/infectious-disease biotechs in a ~$20B buying spree, including a Bothell company for $1.5B, pivoting toward a new infectious disease portfolio. The multi-deal announcement signals Lilly is deploying GLP-1 cash flows into pipeline diversification, but raises capital-allocation risk for a stock already priced for perfection near $1,085.
0 reads·0 theses
Angle
↓ SHORT-5% target+3% stop1-2 weeksJun 11 '25
Fade the LLY pop short-term — three simultaneous acquisitions totaling ~$20B signal management urgency, and with insiders selling and the stock up 1.9% on the day, the risk/reward favors a tactical short into the Goldman conference.